| Identification | Back Directory | [Name]
(2S,4R)-1-[(2R)-2-[3-[(1S)-2-[(3R)-3-[(6aS)-5,6,6a,7,9,10-Hexahydro-2-(2-hydroxyphenyl)-8H-pyrazino[1′,2′:4,5]pyrazino[2,3-c]pyridazin-8-yl]-1-pyrrolidinyl]-1-methylethoxy]-5-isoxazolyl]-3-methyl-1-oxobutyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-5-thiazolyl)phenyl]ethyl]-2-pyrrolidinecarboxamide | [CAS]
2755761-78-3 | [Synonyms]
(2S,4R)-1-[(2R)-2-[3-[(1S)-2-[(3R)-3-[(6aS)-5,6,6a,7,9,10-Hexahydro-2-(2-hydroxyphenyl)-8H-pyrazino[1′,2′:4,5]pyrazino[2,3-c]pyridazin-8-yl]-1-pyrrolidinyl]-1-methylethoxy]-5-isoxazolyl]-3-methyl-1-oxobutyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-5-thiazolyl)phenyl]ethyl]-2-pyrrolidinecarboxamide | [Molecular Formula]
C47H58N10O6S | [MOL File]
2755761-78-3.mol | [Molecular Weight]
891.09 |
| Hazard Information | Back Directory | [Uses]
PRT3789 is a SMARCA2 PROTAC degrader (DC50 in HeLa cell: 0.72 nM for SMARCA2, 14 nM for SMARCA4). PRT3789 shows synergistic anti-proliferation effects with Adagrasib (HY-130149) in cancer cells. PRT3789 inhibits SMARCA4-mutated lung cancer proliferation. PRT3789 inhibits tumor growth in SMARCA4-deleted NSCLC models. Pink: SMARCA4 ligand (HY-44824) ; Blue: VHL ligand (HY-159465) ; Black: linker; VHL ligand+linker (HY-172738)[1]. | [References]
[1] Koichi Ito, et al. Improved treatment of cancers using combinations of smarca2 degraders and kras targeting therapies. Patent. WO2024076985A2 |
|
|